A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

  • Respiratory Disorder
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Aarhus
  • Adelaide
  • Athens
  • Aveiro
  • Bad Berka
  • Be'er Sheva
  • Berlin
  • Birmingham
  • Bristol
  • Brno-Bohunice
  • Bruxelles
  • Cambridge
  • Camperdown
  • Chaidari
  • Coimbra
  • Dublin
  • Dublin 4
  • Edinburgh
  • Exeter
  • Firenze
  • Forlì
  • Gdańsk
  • Gießen
  • Haifa
  • Hamilton
  • Heidelberg
  • Hellerup
  • Hlavní město Praha
  • Iraklio
  • Jerusalem
  • Jihlava
  • Kefar Sava
  • L'Hospitalet de Llobregat
  • Leicester
  • Leuven
  • London
  • Madrid
  • Manchester
  • Melbourne
  • Milano
  • Milton
  • Murdoch
  • München
  • New Lambton Heights
  • Odense
  • Olomouc
  • Petah Tikva
  • Porto
  • Rehovot
  • Sanatorio San Luigi
  • Santander
  • Sheffield
  • Southampton
  • Stoke-on-Trent
  • Torrette
  • Vancouver
  • Vila Nova de Gaia
  • Warszawa
  • Woolloongabba
  • Łódź
Trial Identifier:

NCT03099187 2016-002744-17 MA39189

  • Royal Prince Alfred Hospital

    2050CamperdownAustralia
  • John Hunter Hospital; Respiratory Department; Respiratory Department

    2305New Lambton HeightsAustralia
  • Lung Research Queensland

    4064MiltonAustralia
  • Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine

    4102WoolloongabbaAustralia
  • Royal Adelaide Hospital; Respiratory Clinical Trials Unit, Thoracic Medicine

    5000AdelaideAustralia
  • Respiratory Department

    3084HeidelbergAustralia
  • The Alfred Hospital

    3004MelbourneAustralia
  • Fiona Stanley Hospital; Advanced Lung Disease Unit

    6150MurdochAustralia
  • ULB Hôpital Erasme

    1070BruxellesBelgium
  • Cliniques Universitaires St-Luc

    1200BruxellesBelgium
  • UZ Leuven Gasthuisberg

    3000LeuvenBelgium
  • Pacifica Lung Research Center/St. Paul's Hospital

    V6Z 1Y6VancouverCanada
  • St. Joseph's Healthcare Hamilton

    L8N 4A6HamiltonCanada
  • Fakultni Nemocnice Brno-Bohunice; Klinika Tuberkulozy A Respiracnich Chorob

    625 00Brno-BohuniceCzechia
  • Nemocnice Jihlava

    586 01JihlavaCzechia
  • Fakultni nemocnice Olomouc; Pneumologicka klinika

    779 00OlomoucCzechia
  • Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci

    121 11Hlavní město PrahaCzechia
  • Aarhus Universitetshospital; Lungesygdomme, Forskning

    8200AarhusDenmark
  • Gentofte Hospital, Lungemedicinsk Afdeling

    2900HellerupDenmark
  • Odense Universitetshospital, Lungemedicinsk Afdeling J

    5000OdenseDenmark
  • Zentralklinik Bad Berka GmbH; Pneumologie

    99438Bad BerkaGermany
  • Evang. Lungenklinik Berlin Klinik für Pneumologie

    13125BerlinGermany
  • Klinik der Justus-Liebig-Universität; Innere Medizin

    35392GießenGermany
  • Thoraxklinik Heidelberg gGmbH

    69126HeidelbergGermany
  • Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V

    81377MünchenGermany
  • Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology

    115 27AthensGreece
  • University General Hospital of Athens "Attikon", B' University Pulmonary Clinic

    124 62ChaidariGreece
  • University General Hospital of Heraklio, Pulmonary Clinic

    IraklioGreece
  • Mater Misericordiae University hospital

    D07 R2WYDublinIreland
  • Soroka; Pulmonary Clinic

    Be'er ShevaIsrael
  • Carmel Medical Center; Pulmonary Institute

    3436212HaifaIsrael
  • Shaare Zedek Medical Center; Pulmonary Inst.

    9103102JerusalemIsrael
  • Hadassah Medical Center; Pulmonary Institute

    JerusalemIsrael
  • Meir Medical Center; Pulmonary Dept

    4428164Kefar SavaIsrael
  • Beilinson Medical Center; Pulmonary Inst.

    4941492Petah TikvaIsrael
  • Kaplan Medical Center

    RehovotIsrael
  • Ospedale Morgagni-Pierantoni; U.O. Pneumologia

    47121ForlìItaly
  • Ospedale San Giuseppe; U.O. di Pneumologia

    20123MilanoItaly
  • A.O.U. Ospedali Riuniti Umberto I -G.M. Lancisi-G. Salesi Ancona; SOD Pneumologia

    60126TorretteItaly
  • A.O. Universitaria San Luigi Gonzaga di Orbassano; Ambulatorio per le Malattie Rare del Polmone

    10043Sanatorio San LuigiItaly
  • Azienda Ospedaliero-Universitaria Careggi; SOD Pneumologia e Fisiopatologia Toracico Polmonare

    50139FirenzeItaly
  • Uniwersyteckie Centrum Kliniczne;Klinika Alergologii i Pneumonologii

    80-214GdańskPoland
  • Uniwersytecki Szpital Kliniczny Nr 1 im.N.Barlickiego Oddzial Kliniczny Pneumonologii i Alergologii

    90-153ŁódźPoland
  • Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc

    01-138WarszawaPoland
  • Hospital Infante D. Pedro; Servico de Pneumologia

    3810-164AveiroPortugal
  • HUC; Servico de Pneumologia A

    3004-561CoimbraPortugal
  • Hospital de Sao Joao; Servico de Pneumologia

    4200-319PortoPortugal
  • CHVNG/E_Unidade 1; Servico de Pneumologia

    4434-502Vila Nova de GaiaPortugal
  • Hospital Universitari de Bellvitge ; Servicio de Neumologia

    08907L'Hospitalet de LlobregatSpain
  • Hospital Universitario Marques de Valdecilla; Servicio de neumologia

    39008SantanderSpain
  • Hospital Universitario La Princesa; Servicio de Neumologia

    28006MadridSpain
  • Hospital Clínico San Carlos - Servicio de Neumologia

    28040MadridSpain
  • Hospital Universitario 12 de Octubre; Servicio de Neumologia

    28041MadridSpain
  • University Hospital Birmingham Queen Elizabeth Hospital

    B15 2GWBirminghamUnited Kingdom
  • Southmead Hospital; Respiratory Department

    BS10 5NBBristolUnited Kingdom
  • Papworth Hospital NHS Foundation Trust; Respiratory Department

    CB2 0AYCambridgeUnited Kingdom
  • Edinburgh Royal Infirmary; Respiratory Department

    EH16 4SAEdinburghUnited Kingdom
  • Royal Devon and Exeter Hospital (Wonford)

    EX2 5DWExeterUnited Kingdom
  • Glenfield Hospital

    LE3 9QPLeicesterUnited Kingdom
  • University College London Hospital; Respiratory Medicine

    NW1 2BULondonUnited Kingdom
  • Royal Brompton Hospital; Respiratory Department

    SW3 6NPLondonUnited Kingdom
  • Wythenshawe Hospital; North West Lung Research Centre

    M23 9GFManchesterUnited Kingdom
  • Northern General Hospital

    S5 7AUSheffieldUnited Kingdom
  • Southampton University Hospitals NHS Trust

    SO16 6YDSouthamptonUnited Kingdom
  • Royal Stoke University Hospital

    ST4 6QGStoke-on-TrentUnited Kingdom
  • St Vincents University Hospital

    D04 T6F4Dublin 4Ireland
    Show trial locations

    The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

    The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Results Disclaimer

    Trial Summary

    The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

    Hoffmann-La Roche Sponsor
    Phase 2 Phase
    NCT03099187, MA39189, 2016-002744-17 Trial Identifier
    Pirfenidone, Placebo Treatments
    Lung Diseases, Interstitial Condition
    Official Title

    Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD

    Eligibility Criteria

    All Gender
    ≥18 Years & ≤ 85 Years Age
    No Healthy Volunteers
    Inclusion Criteria
    • Age >= 18-85 years
    • Confirmed fibrosing ILD which, following multidisciplinary team review, cannot be classified with either high or moderate confidence as a specific idiopathic interstitial pneumonia or other defined ILD
    • Progressive disease as considered by the investigator as participants deterioration within the last 6 months, which is defined as a rate of decline in forced vital capacity (FVC) >5% or a significant symptomatic worsening not due to cardiac, pulmonary vascular or other causes
    • Extent of fibrosis >10% on high-resolution computed tomography
    • Forced vital capacity >= 45% of predicted value
    • Diffusing capacity of the lung for carbon monoxide (DLco) >= 30% of predicted value
    • Forced expiratory volume in 1 second/FVC ratio >= 0.7
    • Able to do 6-minute walk distance (6MWD) >= 150 meters
    • For women of childbearing potential: agreement to remain abstinent or use a non-hormonal or hormonal contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of pirfenidone
    • For men, agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm
    Exclusion Criteria
    • Diagnosis with moderate or high confidence of nonspecific interstitial pneumonia and any ILD with an identifiable cause such as connective tissue disease-ILD, chronic hypersensitivity pneumonitis, or others
    • Diagnosis of idiopathic pulmonary fibrosis independent of the confidence level
    • History of unstable angina or myocardial infarction during the previous 6 months
    • Treatment with high dose systemic corticosteroids, or any immunosuppressant other than mycophenolate mofetil/acid (MMF), at any time within the 4 weeks of the screening period. Participants being treated with MMF should be on a stable dose that is expected to remain stable throughout the trial and was started at least 3 months prior to screening
    • Participants previously treated with pirfenidone or nintedanib
    • Participants treated with N-acetyl-cysteine for fibrotic lung disease, at any time within the 4 weeks of the screening period
    • Drug treatment for any type of pulmonary hypertension
    • Participation in a trial of an investigational medicinal product within the last 4 weeks
    • Significant other organ co-morbidity including hepatic or renal impairment
    • Predicted life expectancy < 12 months or on an active transplant waiting list
    • Use of any tobacco product in the 12 weeks prior to the start of screening, or any unwillingness to abstain from their use through to the Follow-up Visit
    • Illicit drug or alcohol abuse within 12 months prior to screening
    • Planned major surgery during the trial
    • Hypersensitivity to the active substance or to any of the excipients of pirfenidone
    • History of angioedema
    • Concomitant use of fluvoxamine
    • Clinical evidence of any active infection
    • Any history of hepatic impairment, elevation of transaminase enzymes, or liver function test results as: Total bilirubin above the upper limit of normal (ULN), Aspartate aminotransferase or alanine aminotransferase >1.5 × ULN, and Alkaline phosphatase >2.0 × ULN
    • Creatinine clearance < 30 milliliter (mL) per minute, calculated using the Cockcroft-Gault formula
    • Any serious medical condition, clinically significant abnormality on an Electrocardiogram (ECG) at screening, or laboratory test results
    • An ECG with a heart rate corrected QT interval using Fridericia's formula as >= 500 milliseconds at screening, or a family or personal history of long QT syndrome

    About Clinical Research

    What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

    Find out now